Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;19(9):573-581.

How we treat mycosis fungoides and Sézary syndrome

Niloufer Khan  1 , Sarah J Noor  2 , Steven Horwitz  1
Affiliations

How we treat mycosis fungoides and Sézary syndrome

Niloufer Khan et al. Clin Adv Hematol Oncol. 2021 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures

Dr Khan has received research funding from Seagen. Dr Noor has served on the medical advisory board for Kyowa Kirin. Dr Horwitz has consulted for, received honoraria from, or participated in advisory boards for Acrotech Biopharma, C4 Therapeutics, Kyowa Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seagen, SecuraBio, Shoreline Biosciences, Takeda, Trillium Therapeutics, Tubulis, and Vividion Therapeutics. In addition, Dr Horwitz has received research support for clinical trials from ADC Therapeutics, Affimed, Celgene, Daiichi Sankyo, Kyowa Kirin, Millennium/Takeda, Seagen, and Verastem/SecuraBio.

Figures

Figure 1.
Figure 1.
A 47-year-old woman with stage IA mycosis fungoides who was started on narrow-band ultraviolet B phototherapy. She initially had a good response, but a few thicker plaques developed after 6 months of phototherapy.
Figure 2.
Figure 2.
A 65-year-old woman with mycosis fungoides who received treatment with narrow-band ultraviolet B phototherapy, focal radiation to the tumors, oral methotrexate, and romidepsin. After 9 months of romidepsin, another skin plaque developed.
See this image and copyright information in PMC

References

    1. Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005;141(3):325–330. - PubMed
    1. Wright A, Wijeratne A, Hung T, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manage. 2013;45(1):114–119. - PubMed
    1. Olsen E, Vonderheid E, Pimpinelli N, et al. ; ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722. - PubMed
    1. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2):223.e221–217; quiz 240–222. - PubMed
    1. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998;134(8):949–954. - PubMed

LinkOut - more resources